Results 71 to 80 of about 16,441 (147)

The Efficacy of Andexanet Alfa for the Reversal of Factor Xa Inhibitors Is Not Influenced by Hemodilution with Different Volume Expanders. [PDF]

J Clin Med
Wienhold J, Rossaint R, Vandeput E, Grottke O.   +3 more
europepmc   +1 more source

An Evaluation of Time to Therapeutic Range of Intravenous Unfractionated Heparin After Transitioning From Direct Oral Factor Xa Inhibitors. [PDF]

Hosp Pharm, 2023
Lawing L, Yook J, Ray M, Smith SE.
europepmc   +1 more source

Safety and Efficacy of Oral Direct Factor Xa Inhibitors in Patients With Nephrotic Syndrome: Results From a National Retrospective Study. [PDF]

Kidney Int Rep
Arches C, Jalal-Eddine A, Titeca-Beauport D, Dao M, Lobbedez T, Zaoui P, Masset C, Bertrand D, El Karoui K, Brenier H, Sakhi H, Peiffer B, Audard V, Joher N.   +13 more
europepmc   +1 more source

The impact of factor Xa inhibitors on bleeding risk in patients with respiratory diseases. [PDF]

Sci Rep
Hamada S, Muramoto K, Akaike K, Okabayashi H, Masunaga A, Tomita Y, Ichiyasu H, Sakagami T.   +7 more
europepmc   +1 more source

Development of a Medication-Use Evaluation Template for Andexanet Alfa in the Reversal of Anticoagulation With Factor Xa Inhibitors. [PDF]

J Pharm Pract
Fera T, Burnett A, Grandoni J, Moore MR, Nussbaum BB, Pollack CV, Rose AE, Spinler SA, Streiff MB, Turck CJ, Fanikos J.   +10 more
europepmc   +1 more source

Venous thromboembolism treatment failure during use of factor Xa inhibitors-association with thoracic outlet syndrome and development of chronic thromboembolic pulmonary hypertension. [PDF]

Ann Med
Kaksonen M, Simonen P, Lassila R, Pentikäinen M.   +3 more
europepmc   +1 more source

Incidence and Predictors of Clinical Outcomes in Real-Life Patients With Atrial Fibrillation Treated With Oral Factor Xa Inhibitors: The Follow-Up Results of the ANATOLIA-AF Study. [PDF]

Clin Cardiol
Kocabaş U, Ergin I, Sönmez SC, Yavuz V, Murat S, Özdemir IH, Genç Ö, Tüner H, Meriç BK, Aslan O, Dal A, Taşkın U, Şen T, İbişoğlu E, Erdoğan A, Özgeyik M, Demir M, Urgun ÖD, Doğduş M, Çakal S, Çayırlı S, Güler A, Karabulut D, Dalgıç O, Murat B, Karabulut U, Öztekin GMY, Biter Hİ, Sinan ÜY, Barış VÖ, Kaplan M, Altın C, Kıvrak T.   +32 more
europepmc   +1 more source

Heavy menstrual bleeding on direct factor Xa inhibitors: the MEDEA randomized clinical trial. [PDF]

Res Pract Thromb Haemost
Hamulyák EN, Wiegers HMG, Hutten BA, de Lange ME, Timmermans A, Westerweel PE, Nijziel MR, Klok FA, Hovens MM, Kamphuisen PW, Büller HR, Middeldorp S, Scheres LJJ.   +12 more
europepmc   +1 more source

3-Factor prothrombin complex concentrate versus 4-factor prothrombin complex concentrate for the reversal of oral factor Xa inhibitors. [PDF]

J Thromb Thrombolysis
Hays WB, Billups K, Nicholson J, Bailey AM, Gregory H, Weeda ER, Weant KA.   +6 more
europepmc   +1 more source

Factor Xa Inhibitor

Japanese Journal of Thrombosis and Hemostasis, 2003
Takashi KOIZUMI, Masahiko UCHIDA
openaire   +2 more sources